FDA Clears IND for Immunome's First-in-Class ADC IM-1340
IMNM sits 96% above its 52-week low of $11.09.
Summary
Immunome received FDA clearance to begin clinical trials for IM-1340, a potential first-in-class antibody-drug conjugate targeting solid tumors. The Phase 1 dose-escalation study is expected to start in Q4 2026. This adds a fourth clinical-stage ADC to the company's pipeline and validates its HC74 payload platform. The news follows the recent FDA acceptance of the varegacestat NDA, reinforcing the company's regulatory momentum.
At the time of this announcement, IMNM was trading at $21.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $11.09 to $30.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.